245 related articles for article (PubMed ID: 25707361)
1. A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors.
Bendell JC; Kurkjian C; Infante JR; Bauer TM; Burris HA; Greco FA; Shih KC; Thompson DS; Lane CM; Finney LH; Jones SF
Invest New Drugs; 2015 Apr; 33(2):463-71. PubMed ID: 25707361
[TBL] [Abstract][Full Text] [Related]
2. Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer.
Rodon J; Pérez-Fidalgo A; Krop IE; Burris H; Guerrero-Zotano A; Britten CD; Becerra C; Schellens J; Richards DA; Schuler M; Abu-Khalaf M; Johnson FM; Ranson M; Edenfield J; Silva AP; Hackl W; Quadt C; Demanse D; Duval V; Baselga J
Cancer Chemother Pharmacol; 2018 Aug; 82(2):285-298. PubMed ID: 29882016
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of single-agent BEZ235 special delivery system sachet in Japanese patients with advanced solid tumors.
Toyoda M; Watanabe K; Amagasaki T; Natsume K; Takeuchi H; Quadt C; Shirao K; Minami H
Cancer Chemother Pharmacol; 2019 Feb; 83(2):289-299. PubMed ID: 30446785
[TBL] [Abstract][Full Text] [Related]
4. A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma.
Carlo MI; Molina AM; Lakhman Y; Patil S; Woo K; DeLuca J; Lee CH; Hsieh JJ; Feldman DR; Motzer RJ; Voss MH
Oncologist; 2016 Jul; 21(7):787-8. PubMed ID: 27286790
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia.
Lang F; Wunderle L; Badura S; Schleyer E; Brüggemann M; Serve H; Schnittger S; Gökbuget N; Pfeifer H; Wagner S; Ashelford K; Bug G; Ottmann OG
BMC Pharmacol Toxicol; 2020 Sep; 21(1):70. PubMed ID: 32993794
[TBL] [Abstract][Full Text] [Related]
6. Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer.
Massard C; Chi KN; Castellano D; de Bono J; Gravis G; Dirix L; Machiels JP; Mita A; Mellado B; Turri S; Maier J; Csonka D; Chakravartty A; Fizazi K
Eur J Cancer; 2017 May; 76():36-44. PubMed ID: 28282611
[TBL] [Abstract][Full Text] [Related]
7. A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies.
Wise-Draper TM; Moorthy G; Salkeni MA; Karim NA; Thomas HE; Mercer CA; Beg MS; O'Gara S; Olowokure O; Fathallah H; Kozma SC; Thomas G; Rixe O; Desai P; Morris JC
Target Oncol; 2017 Jun; 12(3):323-332. PubMed ID: 28357727
[TBL] [Abstract][Full Text] [Related]
8. A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer.
Wei XX; Hsieh AC; Kim W; Friedlander T; Lin AM; Louttit M; Ryan CJ
Oncologist; 2017 May; 22(5):503-e43. PubMed ID: 28314838
[TBL] [Abstract][Full Text] [Related]
9. A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors.
Mehnert JM; Edelman G; Stein M; Camisa H; Lager J; Dedieu JF; Ghuysen AF; Sharma J; Liu L; LoRusso PM
Invest New Drugs; 2018 Feb; 36(1):36-44. PubMed ID: 28417284
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma.
Seront E; Rottey S; Filleul B; Glorieux P; Goeminne JC; Verschaeve V; Vandenbulcke JM; Sautois B; Boegner P; Gillain A; van Maanen A; Machiels JP
BJU Int; 2016 Sep; 118(3):408-15. PubMed ID: 26779597
[TBL] [Abstract][Full Text] [Related]
11. Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors.
Jänne PA; Cohen RB; Laird AD; Macé S; Engelman JA; Ruiz-Soto R; Rockich K; Xu J; Shapiro GI; Martinez P; Felip E
J Thorac Oncol; 2014 Mar; 9(3):316-23. PubMed ID: 24496004
[TBL] [Abstract][Full Text] [Related]
12. A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors.
Grilley-Olson JE; Bedard PL; Fasolo A; Cornfeld M; Cartee L; Razak AR; Stayner LA; Wu Y; Greenwood R; Singh R; Lee CB; Bendell J; Burris HA; Del Conte G; Sessa C; Infante JR
Invest New Drugs; 2016 Dec; 34(6):740-749. PubMed ID: 27450049
[TBL] [Abstract][Full Text] [Related]
13. Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors.
Yamada K; Yamamoto N; Yamada Y; Nokihara H; Fujiwara Y; Hirata T; Koizumi F; Nishio K; Koyama N; Tamura T
Clin Cancer Res; 2011 Apr; 17(8):2528-37. PubMed ID: 21372218
[TBL] [Abstract][Full Text] [Related]
14. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors.
Markman B; Tabernero J; Krop I; Shapiro GI; Siu L; Chen LC; Mita M; Melendez Cuero M; Stutvoet S; Birle D; Anak Ö; Hackl W; Baselga J
Ann Oncol; 2012 Sep; 23(9):2399-2408. PubMed ID: 22357447
[TBL] [Abstract][Full Text] [Related]
15. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.
Papadopoulos KP; Tabernero J; Markman B; Patnaik A; Tolcher AW; Baselga J; Shi W; Egile C; Ruiz-Soto R; Laird AD; Miles D; Lorusso PM
Clin Cancer Res; 2014 May; 20(9):2445-56. PubMed ID: 24583798
[TBL] [Abstract][Full Text] [Related]
16. A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours.
Fazio N; Buzzoni R; Baudin E; Antonuzzo L; Hubner RA; Lahner H; DE Herder WW; Raderer M; Teulé A; Capdevila J; Libutti SK; Kulke MH; Shah M; Dey D; Turri S; Aimone P; Massacesi C; Verslype C
Anticancer Res; 2016 Feb; 36(2):713-9. PubMed ID: 26851029
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
Guo F; Letrent SP; Munster PN; Britten CD; Gelmon K; Tolcher AW; Sharma A
Cancer Chemother Pharmacol; 2008 Jun; 62(1):97-109. PubMed ID: 17805538
[TBL] [Abstract][Full Text] [Related]
18. A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers.
Roohullah A; Cooper A; Lomax AJ; Aung J; Barge A; Chow L; McHale M; Desai J; Whittle JR; Tran B; de Souza P; Horvath LG
Invest New Drugs; 2018 Oct; 36(5):886-894. PubMed ID: 29766337
[TBL] [Abstract][Full Text] [Related]
19. Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.
Awan FT; Gore L; Gao L; Sharma J; Lager J; Costa LJ
Br J Haematol; 2016 Oct; 175(1):55-65. PubMed ID: 27293194
[TBL] [Abstract][Full Text] [Related]
20. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
Bendell JC; Rodon J; Burris HA; de Jonge M; Verweij J; Birle D; Demanse D; De Buck SS; Ru QC; Peters M; Goldbrunner M; Baselga J
J Clin Oncol; 2012 Jan; 30(3):282-90. PubMed ID: 22162589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
